Target intelligence / Profile preview

Klebsiella pneumoniae surface antigens

Molecular classification
Other
01

Overview

Klebsiella pneumoniae surface antigens are a diverse group of molecules, including capsular polysaccharides (K-antigens), lipopolysaccharides (O-antigens), and outer membrane proteins, that are critical for the bacterium's survival and pathogenicity. The capsular polysaccharide (CPS) forms a thick protective layer that allows the pathogen to evade the host immune system by inhibiting phagocytosis and complement-mediated killing (1.1.2, 1.3.4). Lipopolysaccharides, specifically the O-antigen component, contribute to serum resistance and act as potent triggers for the host's innate immune response (1.2.3, 1.3.1). Additionally, surface structures like type I and type III fimbriae (e.g., MrkA) facilitate bacterial adhesion to host tissues and the formation of biofilms, which are essential for establishing persistent and antibiotic-resistant infections (1.2.1, 1.2.4). These antigens are primary targets for the development of vaccines and monoclonal antibodies, which aim to opsonize the bacteria or neutralize their virulence (1.3.3, 1.3.5). However, the extreme diversity of serotypes—with over 140 K-antigens identified—remains a significant challenge for achieving broad-spectrum therapeutic protection (1.3.5, 1.4.2).

Other names
K-antigenO-antigenCapsular polysaccharide (CPS)Lipopolysaccharide (LPS)Outer membrane proteins (OMPs)FimbriaePiliKlebsiella surface polysaccharides
02

Mechanism of action

Opsonization, Neutralization of virulence factors, Inhibition of bacterial adhesion, Complement activation, and Induction of protective humoral immunity.

03

Biological functions

Immune evasionAdhesionBiofilm formationProtectionSignal transduction
04

Disease associations

InfectionSepsisPneumoniaUrinary tract infectionLiver abscess
05

Safety considerations

Serotype replacementEndotoxin-mediated inflammatory responseCapsule masking of underlying antigensHigh antigenic diversity limiting broad coverage
06

Interacting drugs

Klebvax

6 more in the full profile.

07

Biomarkers

K-serotype (e.g., K1, K2)O-serotype (e.g., O1, O2)wzi gene sequencewzc gene sequence

Beyond the preview

Go deeper on Klebsiella pneumoniae surface antigens.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Klebsiella pneumoniae surface antigens.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call